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1. Introduction 
Gliomas account for almost half of all diagnosed adult brain tumors (Siker et al., 2006). 
Glioblastoma multiforme (GBM), the most aggressive type of glioma, is also the most 
common primary malignant brain tumor. Even though tremendous effort has been made to 
treat high grade gliomas, the prognosis for patients with malignant gliomas remains poor. 
The dismal prognosis of patients with glioblastoma is in part caused by the resistance of 
these tumors to both chemotherapy and radiation. Furthermore, high grade gliomas often 
diffusely infiltrate into neighboring brain tissue, thus complicating treatment and commonly 
preventing a cure for the disease. Treatment modalities containing chemotherapy often have 
high levels of toxicity and depending on the drug have to be locally injected as crossing the 
blood-brain barrier is an impediment for certain drug therapies. The addition of 
temozolomide (TMZ) to the standard of care treatment for GBM in 2005 circumvented the 
aforementioned problems as it is taken orally, crosses the blood-brain barrier, and has a 
relatively low toxicity profile. However, the average life expectancy of patients treated with 
the addition of temozolomide increased by only a couple of months. Therefore, more 
effective treatment strategies are critically needed for the treatment of gliomas. In recent 
years, the research efforts in identifying molecular biomarkers for tumor subtypes have 
exponentially increased. These biomarkers can help serve a diagnostic role by helping 
classify grade or subtype, as well as a predictive role in determining the expected response 
to a specific treatment, and/or a prognostic role in estimating the natural course of the 
disease. Furthermore, gaining a better understanding of the molecular mechanisms involved 
in gliomagenesis, migration, and tumor resistance is essential for identifying novel tumor 
targets to overcome the poor prognosis of patients harboring gliomas. Additionally, 
characterizing the best treatment(s) for each grade and molecular subtype of gliomas will 
enable clinicians to increase efficacy of therapies for patients. The ability to categorize 
tumors based on molecular biomarkers for each glioma grade will further enhance the 
effectiveness of treatments by broadening the therapeutic window between normal and 
malignant tissues. In this chapter, molecular mechanisms (see Figure 1) and genetic 
alterations underlying the etiology of gliomas, corresponding molecular biomarkers (see 
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Table 1) within the discussed pathways, and novel targeted therapies currently being 
investigated (see Table 2) are reviewed in detail.  
 
 
Fig. 1. Growth Factor Signaling Pathways in Malignant Gliomas and Corresponding 
Targeted Therapies 
2. Molecular mechanisms contributing to gliomas, corresponding molecular 
biomarkers, and relevant targeted therapies 
2.1 LOH of 1p/19q  
Loss of heterozygosity (LOH) of chromosomes 1p and 19q is the most common genetic 
alteration in oligodendroglioma tumors (Gladson et al., 2010). This hallmark alteration is 
detected in 40-90% of oligodendrogliomas (Cairncross & Jenkins, 2008; Gladson et al., 2010; 
Jansen et al., 2010; Riemenschneider et al., 2010) and can be readily detected by fluorescent 
in situ hybridization (FISH) or southern blotting in the pathology lab. Therefore, loss of 
1p/19q is used as a diagnostic marker of oligodendrogliomas. Co-deletion of 1p/19q is also 
found in 20-30% of mixed glial tumors (Aldape et al., 2007) and <10% of diffuse astrocytic 
gliomas (including GBMs) (Riemenschneider et al., 2010) . Although the regions of 
chromosomes 1p and 19q have been mapped, the actual tumor suppressor genes whose loss 
is involved in the promotion of growth in oligodendroglioma tumors are yet to be 
identified.  
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Interestingly, LOH at these loci confers a favorable response to chemotherapy, radiation, 
and survival (Nutt, 2005; Gladson et al., 2010). Exactly how the unidentified genes on 
chromosomes 1p and 19q contribute to a more favorable therapeutic response remains to be 
determined. Initially, the favorable response was first observed in a large percentage 
(approximately two-thirds) of patients with anaplastic oligodendrogliomas (grade III) that 
had a sustained response to chemotherapy. In 1998, Cairncross and colleagues first 
identified that coincident loss of chromosomal arms 1p and 19q confers chemotherapeutic 
sensitivity, prolonged recurrence-free and overall survival in patients with anaplastic 
oligodendroglioma (AO) treated with combination of procarbazine, lomustine and 
vincristine (PCV) chemotherapy (Cairncross et al., 1998). Following this discovery, interest 
in the use of chemotherapy for patients with oligodendroglial or mixed gliomas 
(oligoastrocytoma) was the impetus behind several clinical trials that corroborated these 
findings. In a series of 162 patients with either pure or mixed glioma, Smith et al. showed 
that the combined loss of 1p and 19q is a statistically significant predictor of prolonged 
survival in patients with pure oligodendroglioma, independent of tumor grade (Smith et al., 
2000). No such association was demonstrated in patients with astrocytic neoplasms. All 
patients with the co-deletion were alive after a median follow-up of 67.5 months, as opposed 
to 73% of those without the combined deletion. In this study, loss of 1p or 19q in isolation 
was not a significant predictor of overall survival in any of the subtypes examined, but 
patients with pure oligodendroglioma did demonstrate a trend (p = 0.15) toward better 
survival if their tumors exhibited loss of 1p or loss of 19q. In another series, 50 patients with 
anaplastic oligodendroglioma were treated with a chemotherapeutic regimen (PCV in 48 
patients) as the main initial adjuvant therapy, and patients with combined deletion of 1p 
and 19q had marked and durable responses to chemotherapy, resulting in longer overall 
survival, with or without postoperative radiation therapy (Ino et al., 2001). Patients with 
chromosome 1p alterations also responded superiorly to chemotherapy, but had shorter 
duration of response and patient survival. Tumors lacking 1p loss, but having a TP53 gene 
mutation, responded to chemotherapy but recurred quickly. The group that fared the worst 
included tumors with intact 1p and wild-type TP53; these were poorly responsive, 
aggressive tumors that were clinically similar to glioblastomas. Loss of 1p has also been 
shown to increase radiation sensitivity (Bauman et al., 2000). Within the subset of patients 
with anaplastic oligodendroglioma who have the 1p/19q co-deletion, those with polysomy 
of chromosomes 1 and 19 were found to have an earlier recurrence than those without 
polysomy (Snuderl et al., 2009). Hirose and colleagues classified microdissected tissue from 
140 patients with WHO grade II-III supratentorial gliomas based on whole genome profile, 
and reaffirmed that patients with 1p/19q deletion show long progression-free survival, 
while loss of 10q in association with gain of 7p appeared to predict poor outcome (Hirose et 
al., 2011). 
Loss of both 1p and 19q has also been shown to increase sensitivity to temozolomide (TMZ), 
a monofunctional alkylating agent (Kouwenhoven et al., 2006). Due to a more favorable 
toxicity profile of TMZ compared with PCV, Radiation Therapy Oncology Group (RTOG) 
conducted a phase II trial of pre-irradiation and concurrent TMZ in patients with newly 
diagnosed anaplastic or mixed oligoastrocytoma. The objective response rate was 58% (32% 
complete response), and rate of progression during the pre-RT TMZ was only 10%, as 
compared to 20% in historical control with PCV (Vogelbaum et al., 2009). All patients with 
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codeletion of 1p/19q and/or O6-methyl guanine DNA methyltransferase gene (MGMT) 
promoter methylation were free from progression at 6 months. Whether a chemotherapy-
only regimen is sufficient to provide long-term control in patients with 1p/19q co-deleted 
anaplastic oligodendroglioma or mixed oligoastrocytoma without the use of concurrent or 
serial radiotherapy remains to be determined. European Organisation for Research and 
Treatment of Cancer (EORTC) is currently conducting CATNON, a Phase III intergroup trial 
on concurrent and adjuvant TMZ chemotherapy in patients with non-1p/19q deleted 
anaplastic glioma. The objectives of this trial are to assess whether RT concurrent with daily 
TMZ improves OS as compared to no daily TMZ in this patient population, and whether 
adjuvant TMZ improves overall survival as compared to no adjuvant TMZ. 
Due to the overall increased survival of patients with co-deletions it is thought that LOH of 
1p and 19q might be a prognostic marker of increased survival rather than a predictive 
marker of specific therapies. Nevertheless, this classification remains to be determined 
although there are retrospective data that demonstrated absence of increased survival 
without treatment, a result that suggests that 1p/19q co-deletion is a predictive marker of 
favorable response to many treatment regimens since it is not treatment specific 
(Riemenschneider et al., 2010).  
Furthermore, there are common alterations that are found with 1p/19q co-deletion, such as 
isocitrate dehydrogenase 1 (IDH1) and IDH2 mutations (Yan et al., 2009). LOH of 1p/19q 
also has been shown to be mutually exclusive of TP53 mutations, 10q deletion, and 
amplification of epidermal growth factor receptor (EGFR) (Nutt, 2005). Surprisingly, the 
location of the tumor site also appears to be associated with 1p/19q co-deletions (Jansen et 
al., 2010). In glioblastoma, deletions involving 1p and 19q are uncommon, but have been 
identified in a small percentage and appear to predict shortened survival (Smith et al., 2000). 
At the present time in the clinic, determining 1p/19q status is part of the standard of care for 
patients with oligodendroglial tumors, to help guide choice and sequencing of therapy. This 
information often serves as useful information when clinicians are determining the course of 
therapy based on the knowledge that patients with oligodendrogliomas that harbor co-
deletions of chromosomes 1p and 19q will likely survive longer and be more responsive to a 
broad range of treatments.  
2.2 Cell cycle regulation 
2.2.1 p53 
TP53 is the gene that encodes the important tumor suppressor protein, p53. In 1989, further 
karyotypic and LOH analysis defined the location of a tumor suppressor on chromosome 17, 
and the TP53 tumor suppressor gene was later identified to be responsible for alterations in 
GBM at this locus (Van Meir et al., 2010). p53 is often referred to as the “guardian of the 
genome” as it is involved in a multitude of critical processes that regulate normal cell 
function, such as cell cycle control, DNA damage response, cell death, differentiation, and 
inhibition of angiogenesis (Fischer & Aldape, 2010). It is a critical factor in the G1/S 
checkpoint whereby activated p53 can signal increased levels of p21, a CDK2 inhibitor, 
resulting in cell cycle arrest (Van Meir et al., 2010). In the absence of p53, the cell cycle can 
become unregulated and lead to uncontrolled proliferation resulting in tumorigenesis. p53 
prevents excess proliferation from triggering apoptosis because p53 also regulates the 
apoptosis response by controlling pro-apoptotic proteins, such as Bax and Fas (Fischer & 
Aldape, 2010; Van Meir et al., 2010). 
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Low grade astrocytomas often possess inactivating mutations of the tumor suppressor gene, 
TP53. Therefore it is thought that p53 mutations are a hallmark of low-grade gliomas and 
consequently also occur in secondary GBM that arise from lower grade gliomas (Noda et al., 
2009). Loss of p53 is observed in grade II astrocytomas (35-60%), grade III astrocytomas 
(~50%), primary GBM (~30%), and secondary GBM (~60-65%) (Sulman et al., 2009; Bourne 
& Schiff, 2010; Gladson et al., 2010). Additionally, p53 mutations are found in ~44% of grade 
II oligoastrocytoma and ~13% of oligodendroglioma cases (Bourne & Schiff, 2010). 
Overexpression of p53 has also been observed in ~50% of GBM cases (Kim et al., 2010). 
Interestingly, tumors that harbor 1p/19q co-deletions do not contain p53 mutations (Noda 
et al., 2009; Fischer & Aldape, 2010). MDM2, a negative regulator of p53, has also been 
reported to be amplified or mutated in anaplastic astrocytoma (AA) (13-43%) and in 
glioblastoma (~10-27%) (Gladson et al., 2010; Kim et al., 2010). Currently, p53 is not thought 
to be predictive or prognostic (Tabatabai et al., 2010). However, it does have a role in the 
diagnostic setting as it can help distinguish tumor grade. 
2.2.2 Rb/P16INK4A/CDK4  
Rb, also known as the retinoblastoma protein, is a tumor suppressor that is the central 
protein responsible for antiproliferative signaling. Rb blocks proliferation by binding and 
inhibiting the E2F transcription factors, which are necessary for the G1 to S phase transition 
and DNA replication (Fischer & Aldape, 2010; Van Meir et al., 2010). Furthermore, Rb is 
normally inactivated by cyclin D1 and CDK4/CDK6 complexes in order for DNA synthesis 
to proceed. p16, which is located on chromosome 19, is an additional regulator of this 
pathway as it negatively regulates CDK4 and CDK6 and therefore also functions as a tumor 
suppressor (Fischer & Aldape, 2010; Van Meir et al., 2010).  
Inhibition of the Rb pathway is common in high grade gliomas, and tumors usually only 
harbor a single altered component of the pathway (Fischer & Aldape, 2010). Tumor 
progression to anaplastic astrocytomas is typically characterized by common mutations in this 
pathway, such as p16 or Rb mutations and amplification or overexpression of CDK4 (Noda et 
al., 2009; Fischer & Aldape, 2010). Loss of the Rb gene and mutation occur in approximately 
30% and 13-25% of grade II and III astrocytomas, respectively (Gladson et al., 2010). 
Additionally, deletions or mutations of the Rb gene occur in 40% of secondary GBM cases 
(Gladson et al., 2010). The frequency of Rb mutations in all high grade-gliomas is common and 
is estimated to occur in approximately 25% of all cases (Fischer & Aldape, 2010). Deletion or 
mutation of p16INK4A as a consequence of loss of chromosome 9p or hypermethylation 
occurs in approximately 12-62.5% of anaplastic astrocytoma cases (Gladson et al., 2010). p16 
loss has also been reported in 20-57% of GBM cases (Sulman et al., 2009; Kim et al., 2010). 
Interestingly, since cyclins and cyclin-dependent kinase (CDK) inhibitors are subject to 
proteosomal degradation, cell cycle regulation can be modified through proteasome 
inhibitors. Bortezomib, a proteasome inhibitor, has been shown to induce cell death in 
cultured glioma cell lines by decreasing levels of CDK2, CDK4, and E2F4 subsequently 
leading to apoptosis in cultured glioma cell lines (Fischer & Aldape, 2010). Although 
alterations of the Rb pathway are very common in gliomas, it remains to be determined how 
these hallmark mutations will translate into a clinically meaningful target. However, a 
recent study did demonstrate that p16 mutations were strong prognostic indicators of OS in 
GBM patients treated with TMZ (Ang et al., 2010). Recently, two Phase I trials using 
bortezomib with and without concurrent temozolomide and radiotherapy for glioblastoma 
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have been reported, and found the combination to be well-tolerated and safe (Kubicek et al., 
2009; Phuphanich et al., 2010). 
2.3 Proliferation, invasion, and angiogenesis pathways 
2.3.1 IDH 
Isocitrate dehydrogenase (IDH), is an enzyme that catalyzes the conversion of isocitrate into 
┙-ketoglutarate within the citric acid cycle. IDH1 and IDH2 are involved in a variety of 
metabolic processes such as signal transduction, lipid synthesis, oxidative stress, and 
oxidative respiration (Riemenschneider et al., 2010). IDH mutations were initially identified 
to be associated with gliomas in 2008 when a genome-wide mutational analysis was 
conducted in GBM (Riemenschneider et al., 2010; Yen et al., 2010). IDH1 and IDH2 
mutations were also found in lower grade gliomas in addition to glioblastomas, making 
IDH the first discovery of somatic genetic alterations in metabolic enzymes in gliomas (Yen 
et al., 2010). In low grade brain tumors, IDH mutations are common genetic alterations of 
gliomas arising from the astrocytic and oligodendroglial lineage. These mutations are also 
identified in secondary GBMs from a lower grade origin (Fischer & Aldape, 2010; Jansen et 
al., 2010). IDH1 and IDH2 mutations are currently used as diagnostic markers for diffuse 
WHO grade II and III gliomas as well as secondary GBMs (Jansen et al., 2010; 
Riemenschneider et al., 2010). IDH1 and IDH2 mutations are often identified concomitantly 
with 1p/19q co-deletions or p53 mutations (Jansen et al., 2010; Riemenschneider et al., 2010). 
Mutations in the IDH1 gene were identified in approximately 80% of diffuse astrocytomas 
and 85% of secondary glioblastomas. In contrast, only 5% of primary glioblastomas carry an 
IDH mutation (Yan et al., 2009; Fischer & Aldape, 2010).  
It remains to be determined how these alterations cause tumorigenesis, although the 
metabolic role of IDH has been recently examined in the context of oncogenesis. IDH1 
mutations are thought to lead to increased formation of 2-hydroxyglutarate (2HG) through a 
gain of function mutation (Jansen et al., 2010; Riemenschneider et al., 2010; Yen et al., 2010). 
There is evidence that D-2HG can exert a direct inhibitory effect on adenosine 5’ 
triphosphate synthase, which interrupts mitochrondrial processes and gives rise to selective 
pressure to promote metabolic adaptation and a shift towards aerobic glycoysis. This 
metabolic shift could confer a growth advantage in an increased proliferative state, such as 
in tumor progression (Yen et al., 2010). Additionally, another possible tumorigenic role of 
2HG is its involvement in hypoxia-inducible factor 1 alpha (HIF1┙) degradation, thus IDH 
mutations are thought to lead to increased levels of HIF1┙ which can facilitate tumor 
growth (Jansen et al., 2010; Riemenschneider et al., 2010; Yen et al., 2010). Other hypotheses 
on the role of IDH mutations in gliomagenesis that are being explored are its possible 
involvement in angiogenesis, glucose transport, glycolysis, and inhibition of apoptosis 
(Riemenschneider et al., 2010; Yen et al., 2010). Therefore, 2HG has been implicated in 
tumorigenesis, and is thought to be a potential therapeutic target, a serum biomarker for 
cancers harboring IDH1 and IDH2 mutations, and a potential response biomarker. 
Interestingly, there is evidence that D-2HG may be visualized via magnetic resonance 
spectroscopy, which in theory could make it possible to perform non-invasive detection of 
tumors with IDH mutations to help diagnose and guide therapy before surgery (Yen et al., 
2010).  
Patients that harbor IDH mutations appear to have a prognostic advantage compared with 
patients without IDH mutations for all gliomas (Jansen et al., 2010; Riemenschneider et al., 
www.intechopen.com
 
Evolvement of Molecular Biomarkers in Targeted Therapy of Malignant Gliomas 
 
123 
2010). Specifically, somatic mutations were present in 18 of 149 (12%) GBMs and seemed to 
correlate with increased survival, as the overall survival was 31 months in patients with 
IDH mutations compared to 15 months in those without IDH mutations (Jansen et al., 2010). 
Although IDH is a useful diagnostic and prognostic tool, it currently does not appear to be 
able to predict responsiveness to a particular type of therapy (Riemenschneider et al., 2010). 
More clinical trials examining IDH mutations need to be performed to determine its role as a 
predictive molecular biomarker. 
2.3.2 PDGFR 
Platelet-derived growth factor (PDGF) plays an important role in cell proliferation, cell 
migration, and angiogenesis. Thus, PDGF receptor (PDGFR) is classified as producing a pro-
proliferative signal and both the level of PDGF and PDGFRs is important in angiogenesis 
and tumor growth in gliomas (Noda et al., 2009; Gladson et al., 2010). Amplification of 
PDGFR┙ occurs in approximately 7% of oligodendroglial tumors (Gladson et al., 2010). 
Astrocytic tumors commonly (3-33%) exhibit amplification of the PDGFR┙ and/or PDGFR┚ 
genes and of the genes encoding their ligands (Gladson et al., 2010). Also, PDGFR┙ and 
PDGFR┚ amplification occurs in approximately 20-29% of primary GBM and 60% of 
secondary GBM. Due to its frequency, amplification of PDGF appears to be a key regulator 
of gliomagenesis, specifically overexpression of PDGFR┚ was shown to initiate 
gliomagenesis when expressed in the neural stem progenitor cell (Gladson et al., 2010). 
Amplification of PDGFR has also been associated with patient outcome, thus suggesting it 
could serve as a prognostic biomarker (Toedt et al., 2011). Imatinib is an orally administered 
tyrosine kinase inhibitor (TKI) of PDGFR, c-abl and c-kit, and is currently being tested in 
clinical trials to assess its efficacy in malignant gliomas. A multicenter phase II study 
evaluating imatinib plus hydroxyurea in 231 patients with recurrent glioblastoma did not 
demonstrate a clinically meaningful anti-tumor activity (Reardon et al., 2009). Precisely, 
progression-free survival at 6 months and median overall survival were 10.6% and 26.0 
weeks, respectively. A Phase II trial has been initiated by Supko et al. that will test the 
efficacy of tandutinib, a PDGFR┚ inhibitor, in patients with recurrent GBM (Supko, 2009). 
2.3.3 EGFR/NFKBIA  
PDGFR is not the only common growth factor receptor involved in gliomagenesis. 
Epidermal growth factor receptor (EGFR) also promotes a pro-proliferative signal, and is 
another common molecular hallmark of glioblastoma (Fischer & Aldape, 2010). In 1984, 
extra copies of chromosome 7 were identified in malignant gliomas, which resulted in EGFR 
amplification/overexpression (Van Meir et al., 2010). EGFR promotes cell proliferation, 
invasion and angiogenesis, induces resistance to apoptosis, and may mediate radiation 
resistance (Sulman et al., 2009; Gladson et al., 2010). EGFR amplification at 7p12 is the most 
commonly amplified and overexpressed gene in primary GBM (30-70%) (Fischer & Aldape, 
2010; Gladson et al., 2010; Kim et al., 2010; Riemenschneider et al., 2010). Additionally, 
EGFRvIII is the most prominent mutated receptor tyrosine kinase receptor in GBM (Noda et 
al., 2009; Riemenschneider et al., 2010). This mutation occurs in ~50% of GBM cases that 
overexpress EGFR (Riemenschneider et al., 2010). EGFRvIII arises from loss of exons 2 and 7 
which leads to loss of the ligand binding domain, thereby promoting constitutive activation 
of EGFR and the PI3K/AKT pathway (Noda et al., 2009; Jansen et al., 2010). Both EGFR and 
PDGFR coordinate with integrins and other cell adhesion receptors. In glioma tissue, an 
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increase in growth factors as well as receptors is typically observed (Gladson et al., 2010). 
EGFR also contributes to invasion as evidenced by the observation that GBMs harboring 
constitutively active EGFRvIII receptors display a more invasive phenotype than those with 
wild-type EGFR (Fischer & Aldape, 2010). One of the main molecular distinctions between 
primary and secondary GBMs is that primary GBMs tend to have EGFR amplifications (~30-
70%), whereas secondary GBMs that arise from lower grade gliomas tend to not have EGFR 
alterations (~5-8%) (Noda et al., 2009; Sulman et al., 2009; Fischer & Aldape, 2010; Kim et al., 
2010). In addition, EGFR amplifications occur in approximately 15% of grade III anaplastic 
astrocytomas (Sulman et al., 2009; Gladson et al., 2010).  
One example of targeted therapy is the inhibition of EGFR tyrosine kinase (TKI). Several 
studies using EGFR TKIs have shown some anti-tumor activity in patients with 
glioblastoma. EGFR overexpression has been demonstrated in malignant gliomas, and is 
associated with anti-apoptotic tendency conferred by activated signaling pathways, tumor 
survival, and proliferation (Nicholas et al., 2006). Surprisingly, the activity did not correlate 
with the level of EGFR overexpression. Gefinitib and erlotinib are examples of EGFR TKIs 
that inactivate the downstream signaling pathways, and have been tested in the recurrent 
GBM setting (Perez-Soler, 2004). However, clinical studies utilizing EGFR inhibitor 
monotherapy have shown only marginal results for patients with recurrent glioblastoma 
(Rich et al., 2004; Prados et al., 2009; van den Bent et al., 2009). When used in combination 
with ionizing radiation, however, the EGFR inhibitors have been shown to augment the 
anti-proliferative and pro-apoptotic activity induced by ionizing radiation in several human 
cancer cell lines, as well as in mice bearing human colon cancer xenografts, as demonstrated 
by Bianco and colleagues (Bianco et al., 2002). 
RTOG conducted a phase I/II study (0211) utilizing gefitinib with radiotherapy in patients 
with newly diagnosed GBM, and compared with historical studies, the combined therapy 
did not improve survival (Chakravarti, 2006). Prados and colleagues performed a phase II 
study of combining erlotinib with RT and TMZ in patients with newly-diagnosed GBM, and 
demonstrated a 5-month improvement in the median survival with this approach (19.3 
months versus 14.1 months in the combined historical control studies) (Prados et al., 2009). In 
this study, a strong positive correlation between MGMT promoter methylation and survival 
was re-demonstrated. However, other studies utilizing a similar approach of combined 
targeted and conventional therapy showed inferior outcomes and high treatment-related 
toxicity and death rate (Brown et al., 2008; Peereboom et al., 2010).  
The efficacy of EGFR inhibitors remains controversial for newly diagnosed glioblastoma, 
although some patients have been reported to respond dramatically to EGFR inhibitors. To 
reconcile the disparity between EGFR overexpression in glioblastomas (up to 50% tumors) 
with only 10-20% of GBM patients that have a response to EGFR TKIs, biological markers to 
predict treatment response have been reported, and these can potentially be used to identify 
the patients that will derive survival benefit from the addition of an EGFR inhibitor 
(Mellinghoff et al., 2005). Specifically, co-expression of EGFR deletion mutant variant III 
(EGFRvIII) and the tumor-suppressor protein PTEN was significantly associated with a 
clinical response to EGFR TKI. In a recent phase II multicenter trial of EGFRvIII-targeted 
vaccination in 18 patients with glioblastoma who received the standard therapy of gross 
total resection followed by RT and concurrent TMZ, the 6-month PFS after vaccination was 
67%, and median overall survival was 26 months (Sampson et al., 2010). The development of 
specific antibody or delayed-type hypersensitivity to EGFRvIII had a significant effect on 
OS. When these patients recurred, 82% had lost EGFRvIII expression.  
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Resistance to these EGFR inhibitors is thought to be due to other mutations downstream of 
EGFR, such as PTEN inactivation (Noda et al., 2009). Another potential problem with this 
type of targeted therapy is that EGFR activates several downstream pathways that might act 
in parallel to drive oncogenesis. In addition, patients with GBM treated with TMZ that had 
EGFR amplification, maintenance of PTEN, and wild-type p53 and p16 were strong 
prognostic indicators of overall survival (Ang et al., 2010). Furthermore, coexpression of 
normal PTEN and mutant EGFRvIII, combined with lower levels of AKT and overexpressed 
EGFR have been identified as predictive markers of radiation response (Fischer & Aldape, 
2010). Although the predictive and prognostic use of EGFR remains to be completely 
defined, it does appear that there is some correlation with survival and treatment response 
(Tabatabai et al., 2010). In addition, the high percentage of GBM cases with EGFR 
overexpression and EGFR mutations strengthens the possibility that targeted therapy of 
EGFR may be a useful treatment for gliomas.  
Due to high frequency of amplification and activating mutations of EGFR in gliomas, the 
deletion of NFKBIA, an inhibitor of the EGFR-signaling pathway, was hypothesized to be an 
additional putative molecular biomarker of gliomas as well. A recent study examined 790 
human GBM cases for deletions, mutations, or expression of NFKBIA and EGFR (Bredel et 
al., 2010). The molecular data was then correlated to outcome data in 570 patients. The 
results showed that NFKBIA is often deleted, but not mutated in glioblastomas. Most 
deletions occurred in nonclassical subtypes of GBM and were inversely correlated with 
EGFR alterations. Importantly, deletion and decreased expression levels of NFKBIA were 
associated with decreased survival and displayed similar outcomes to patients with EGFR 
amplifications (Bredel et al., 2010).  
2.3.4 VEGF 
The formation of new blood vessels (angiogenesis) is one of the major steps in progression 
of malignant gliomas. Angiogenesis is controlled through many factors, such as vascular 
endothelial growth factor (VEGF) which is controlled by the transcription factor HIF1┙, EGF 
and PDGF (Deighton et al., 2010; Fischer & Aldape, 2010). VEGF is considered to be the 
driving factor of angiogenesis in astrocytic gliomas. It has been identified in grade II 
astrocytoma (36.8%), grade III astrocytoma (66.7%) and in glioblastomas (64.1%) (Oehring et 
al., 1999). Additionally, a strong correlation between VEGF expression and survival was 
identified indicating VEGF as a possible prognostic factor in patients with gliomas (Oehring 
et al., 1999). 
One class of targeted therapy includes antiangiogenic agents that target VEGF. Glioblastoma 
has long been recognized as a highly angiogenic tumor (Ahluwalia & Gladson, 2010). 
Bevacizumab, a humanized monoclonal antibody that recognizes and blocks VEGF, was 
approved by the Food and Drug Administration (FDA) as a second-line or salvage 
treatment of glioblastoma. Recent studies of recurrent glioblastoma have shown that 
bevacizumab improved response rate and progression-free survival, but specific adverse 
effects have also been reported, such as intracranial hemorrhage, gastrointestinal 
perforation, and thromboembolic complications (Vredenburgh, 2010; Friedman, 2009). In 
one study of 73 patients with recurrent high-grade gliomas who already received a VEGFR 
TKI (cediranib, sorafenib, pazopanib, or sunitinib), bevacizumab salvage therapy conferred 
21% radiologic partial response rate; 12.5% patients were alive and progression-free at six 
months, and median overall survivial was 5.2 months (range 1.3-28.9+ months) after 
bevacizumab (Scott et al., 2010). 
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To evaluate its effect in the up-front setting, Lai et al. conducted a phase II study of 
bevacizumab plus TMZ during and after RT for patients with newly diagnosed glioblastoma 
(Lai et al., 2011). They reported a median overall survival and progression-free survival of 
19.6 and 13.6 months, respectively. The authors concluded that the addition of bevacizumab 
improved progression-free survival, but not overall survival, compared with their historical 
studies. Currently, RTOG is conducting a Phase III double-blind placebo-controlled trial of 
conventional concurrent chemoradiation and adjuvant TMZ plus bevacizumab versus 
conventional concurrent chemoradiation and adjuvant TMZ in patients with newly 
diagnosed GBM. Results are awaited, as this study will determine the efficacy of adding 
bevacizumab to the current standard treatment of GBM.  
Sathornsumetee and colleagues recently reported results of a Phase II trial with 
bevacizumab and erlotinib, an EGFR inhibitor, in patients with recurrent high grade gliomas 
(both GBM and anaplastic astrocytoma (AA)). In this trial, the progression-free survival at 
six months (PFS-6) was 28% for patients with GBM and 44% for patients with AA. Median 
overall survival was 42 and 71 weeks for patients with GBM and AA, respectively 
(Sathornsumetee et al., 2010). 
In another study evaluating the efficacy of adding sorafenib, an oral VEGFR TKI, to 
maintenance TMZ following the standard radiotherapy and TMZ in the first-line treatment 
of 47 patients with GBM, the addition of sorafenib did not appear to improve the efficacy of 
the standard therapy (Hainsworth et al., 2010). However, 40% patients in this study did not 
receive any maintenance sorafenib due to early disease progression, lending credence to the 
hypothesis that the administration of angiogenesis inhibitors concurrently with RT and 
TMZ may optimize the opportunity to improve therapy. The aforementioned RTOG Phase 
III trial will help answer this question. 
Cilengitide, one of the other anti-angiogenic drugs, inhibits ┙v┚3 and ┙v┚5 integrin receptors, 
resulting in apoptosis of glioblastoma cells (Taga et al., 2002). Cilengitide monotherapy for 
recurrent glioblastoma has a modest effect and confers an approximate 6-month progression-
free survival of 15% (Reardon et al., 2008). Currently, Stupp and colleagues are conducting 
randomized studies of RT plus TMZ with or without cilengitide for newly diagnosed 
glioblastoma. The Phase I/IIa study of cilengitide and temozolomide with concomitant 
radiotherapy followed by cilengitide and temozolomide maintenance therapy in 52 patients 
with newly diagnosed glioblastoma demonstrated promising activity in patients with MGMT 
promoter methylation. Specifically, 6- and 12-month progression-free survival rates were 69% 
and 33%, while the 12- and 24-month overall survival rates were 68% and 35% for all patients. 
The PFS and OS benefit was most pronounced in patients with MGMT promoter methylation 
(13.4 and 23.2 months versus 2.4 and 13.1 months) (Stupp et al., 2010). 
2.4 Signal transduction pathways 
Alterations of signaling molecules in gliomas are often involved in gliomagenesis. These 
signaling molecules act downstream of the cell surface growth factors and cell adhesion 
receptors to amplify and propagate growth and proinvasion signals. Examples of these 
signaling molecules include: tyrosine kinase FAK, src family tyrosine kinases, RAS, PI3K, 
and PTEN. PI3K and PTEN are molecules that regulate glioma cell survival and 
proliferation. Normally, PI3K promotes proliferation and survival, where as PTEN 
negatively regulates this process. Many glioblastomas have dysregulation of signaling 
cascades downstream of the growth factor, such as PTEN mutations and mutations within 
the PI3K/AKT pathway (Jansen et al., 2010). 
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2.4.1 PI3K/AKT/PTEN pathway 
PTEN (phosphatase and tensin homolog) is a tumor suppressor gene, a negative regulator of 
the P13K/AKT pathway, and a known inhibitor of angiogenesis. It was first identified as a 
tumor suppressor located on chromosome 10 in 1997 (Van Meir et al., 2010). PTEN codes for 
a protein that preferentially dephosphorylates the phosphoinositide substrate, PIP3, and 
once PTEN is lost PIP3 levels accumulate and lead to constitutive P13K signaling and AKT 
activation (Maehama & Dixon, 1998). Thus, it is not surprising that loss of PTEN is 
associated with poor prognosis (Ermoian et al., 2002; Ang et al., 2010; Gladson et al., 2010).  
PTEN mutations are common in ~8% of oligodendrogliomas and there is evidence that the 
presence of this mutation in patients is associated with poor prognosis (Sasaki et al., 2001). 
Downregulation of this gene has also been found in 50% of grade II and grade III 
oligodendrogliomas, which appears to be a consequence of promoter methylation (Wiencke 
et al., 2007; Bourne & Schiff, 2010). In grade II and III astrocytomas, PTEN promoter 
methylation occurs in ~43-67% of cases (Wiencke et al., 2007; Bourne & Schiff, 2010). In 
glioblastoma, PTEN is deleted due to LOH of chromosome 10q in ~50-70% of primary cases 
and ~54-63% secondary cases as well as mutated in ~14-47% of primary cases (Fujisawa et 
al., 2000; Ohgaki et al., 2004). Methylation of the PTEN promoter in glioblastoma (9%) has 
also been observed (Wiencke et al., 2007). In many cases loss of PTEN (50% of high grade 
gliomas) results in unregulated PI3K signaling, AKT activation, and upregulation of mTOR 
(mammalian target of rapamycin) signaling, which increases protein translation through 
activation of S6 kinase 1 (S6K1) and eIF4E-binding protein 1 (4E-BP1) (Fischer & Aldape, 
2010; Zoncu et al., 2011). mTOR signaling is also known to play a role in hypoxic adaptation 
of tumors (Van Meir et al., 2010). 
Currently, PTEN is thought to be a prognostic molecular marker as patients with loss of PTEN 
have decreased survival. Based on preclinical evidence that loss of PTEN activates the mTOR 
pathway, and thereby sensitizes tumors to the inhibition of mTOR, a proof-of-concept Phase I 
trial utilizing neoadjuvant rapamycin in patients with recurrent GBM showed dramatic 
anticancer activity in half of the patients (7/14) (Cloughesy et al., 2008). However, rapamycin 
treatment led to AKT activation in 7/14 patients, implying inadequate inhibition of the mTOR 
complex 2 (mTORC2). In a Phase II trial utilizing CCI-779, a dihydroxylmethyl propionic acid 
ester of sirolimus that targets the mTORC pathway, there was no evidence of efficacy in 
patients with recurrent GBM, as only 1/43 patients was progression-free at 6 months (Chang 
et al., 2005). North Central Cancer Treatment Group Study (NCCTG) conducted a Phase II trial 
of once-weekly intravenous temsirolimus, an mTORC1 inhibitor, in 63 patients with recurrent 
GBM, improving radiographic response in 36% of patients, as well as conferring a significantly 
longer time to progression in responders (5.4 months versus 1.9 months) (Galanis et al., 2005). 
In a more recent Phase I trial by NCCTG, the combination of everolimus, an mTORC1 
inhibitor, with chemoradiotherapy in 18 patients with newly diagnosed GBM showed that the 
combination was reasonably well-tolerated, and Phase II dose established (Sarkaria et al., 
2010). To date, no clinical trials combining inhibition of both the mTORC1 and mTORC2 have 
been reported.  
In recent years, PTEN status has also been examined as a predictive factor for efficiency of 
certain targeted therapies, such as poly (ADP-ribose) polymerase (PARP) inhibitors (Dedes 
et al., 2010; McEllin et al., 2010). It is now known that PTEN is important for maintaining the 
levels of key proteins involved in homologous recombination, such as Rad51B, Rad51C and 
Rad51D (Shen et al., 2007). McEllin and colleagues demonstrated that PTEN-null astrocytes 
had decreased transcript levels of these proteins, consistent with deficiency in homologous 
www.intechopen.com
 
Brain Tumors - Current and Emerging Therapeutic Strategies 
 
128 
recombination in PTEN-null cells. In their experiments, PTEN-null astrocytes were 
significantly more sensitive to PARP inhibitor compared with PTEN-proficient cells 
(McEllin et al., 2010). Data from clinical trials utilizing PARP inhibitors in patients with 
recurrent or newly diagnosed GBM are awaited.  
Mutations of PTEN are not the only molecular markers of gliomas in the PI3K pathway. PI3K 
signaling is an important mediator of cell growth and proliferation, thus its activation is 
frequent and associated with poor prognosis in glioma patients (Fischer & Aldape, 2010). 
Multiple growth factors, such as EGFR, exert their oncogenic effects through activation of 
PI3K/AKT pathway, which is constitutively activated in up to 70% of GBM due to PTEN loss 
(Kreisl et al., 2009). An additional study looking at 84 cases in GBM identified pAKT 
overexpression and PI3K overexpression in 16% and 6% of the cases, respectively (Kim et al., 
2010). Downstream of AKT is the serine/threonine kinase, mammalian target of rapamycin 
(mTOR), which regulates protein biosynthesis, ribosome biogenesis, and the transcription of 
essential genes (Fischer & Aldape, 2010; McBride et al., 2010). As noted above, inhibitors of 
mammalian target of rapamycin (mTOR) have been shown to decrease PI3K/AKT activation, 
and combined mTOR and EGFR inhibition has demonstrated synergy in GBM xenografts 
(Goudar et al., 2005). In a pilot study of everolimus, an mTOR inhibitor, and gefitinib, an EGFR 
inhibitor, in the treatment of 22 patients with recurrent GBM, 36% of patients had stable 
disease and 14% a partial response (PR) (Kreisl et al., 2009). Although disease control was short 
lived (median progression-free survival (PFS) 2.6 months), the patients with PR all had intact 
PTEN, and AKT activation was observed in 80% of tumors in which PTEN was lost. In another 
Phase II study with erlotinib, an EGFR TKI, and sirolimus, an mTOR inhibitor, in 32 patients 
with recurrent GBM, were also well-tolerated, but had negligible activity among unselected 
patients. Precisely, no patients achieved either a complete or partial response, and the 
estimated 6-month progression-free survival for all patients was 3.1%, but somewhat better for 
patients not on enzyme-inducing antiepileptic drugs (Reardon et al., 2010). Of all tumor 
markers tested (EGFR, EGFRvIII, PTEN, pAKT and pS6), only pAKT expression achieved 
borderline significance in association with PFS. Coexpression of EGFR vIII with intact PTEN 
has been shown to predict sensitivity to EGFR inhibitor monotherapy (Mellinghoff et al., 2005).  
Activation of the PI3K/mTOR pathway occurs in most adult low grade gliomas, too 
(McBride et al., 2010). In a recent study, methylation of PTEN, expression of phospho-
PRAS40 and phospho-S6 all correlated with decreased survival which suggests that these 
molecular alterations can be used as prognostic markers for both high and low grade 
gliomas. Phospho-S6 is a downstream mediator of mTOR, whereas PRAS40 is 
phosphorylated by AKT and inhibits negative regulation of mTOR thereby further 
increasing PI3K/AKT signaling (McBride et al., 2010).  
In summary, PTEN may be a possible predictive biomarker of glioma response to specific 
therapies, in addition to its role as a prognostic marker due to its association with aggressive 
tumor phenotypes and survival. Since upregulation of the P13K/mTOR pathway through a 
variety of mechanisms predicts overall decreased survival, the use of selective PI3K, AKT, or 
mTOR inhibitors in the treatment of gliomas appears to be a valid therapeutic target to 
combat gliomagenesis.  
2.4.2 RAS/MAPK pathway 
The MAPK pathway, an additional important signal transduction pathway involved in 
gliomagenesis, is initiated through integrins or receptor tyrosine kinase (RTK) receptors. 
Growth factors can bind to these RTKs, such as TGF-┚, and stimulate the downstream 
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activation of RAS and phosphorylation of MAPK (mitogen-activated protein kinase) by 
MEK. Phosphorylated MAPK then signals the activation of nuclear transcription factors, 
such as genes involved in cell cycle progression (Fischer & Aldape, 2010). MAPK signaling 
is also involved in apoptosis, cell differentiation, and cell migration (Sulman et al., 2009). 
RAS is often activated in gliomas, however it does not usually contain mutations, but rather 
an unregulated RTK or integrin activation (Fischer & Aldape, 2010). Specifically, the rate 
limiting step of RAS activation is farnesylation, which explains the use of farnesyltransferase 
inhibitors in gliomas. Two separate farnesyl transferase inhibitors, tipifarnib and lonafarnib, 
have led to mixed results in clinical trials. A Phase II trial with pre-radiation tipifarnib 
(R115777) in patients with newly diagnosed GBM with residual enhancing disease on 
postoperative MR imaging showed that there were no tumor responses, and the study was 
stopped early due to progression of disease in 12 (48%) patients (Lustig et al., 2008). In a 
Phase II study by North American Brain Tumor Consortium, tipifarnib in patients with 
recurrent malignant glioma showed modest evidence of activity. Precisely, 12% of GBM 
patients had progression-free survival more than 6 months (Cloughesy et al., 2006).  
In terms of biomarkers, MAPK proteins appear to be both predictive and prognostic 
molecular biomarkers. Phosphorylated MAPK was found to be inversely correlated with 
survival, as well as associated with increased radiation resistance (Pelloski et al., 2006). 
Additionally, upregulation of the MAPK pathway can occur through the proto-oncogene 
BRAF. Abnormal activation of BRAF, most commonly by gene duplication and fusion, has 
recently been identified as the characteristic genetic aberration in pilocytic astrocytomas. It 
occurs in ~60-80% of pilocytic astrocytoma cases (Riemenschneider et al., 2010). 
2.5 DNA repair  
2.5.1 MGMT 
DNA repair response is a critical factor that greatly influences the effectiveness of the 
majority of chemotherapy agents and radiation. O6-methyl guanine DNA methyltransferase 
gene (MGMT) is located at chromosome 10q26 and encodes a DNA repair protein that 
removes the alkyl groups from the O6 position of guanine, which are commonly produced 
by chemotherapeutic alkylating agents. MGMT is one of the principal enzymes involved in 
DNA repair, and it is irreversibly inactivated upon removing alkyl groups from the O6 
position of guanine. De novo synthesis of MGMT is required to replenish the enzyme, and 
the MGMT promoter needs to be functional if DNA repair is to take place. The MGMT 
promoter is downregulated by hypermethylation of a CpG island in a 5’ region of the gene 
(Gerson, 2004). Once hypermethylated, the promoter downregulates MGMT and thereby 
hampers this enzyme’s ability to repair DNA damage induced by alkylating agents such as 
temozolomide. Methylation status of the MGMT promoter, as well as its association with 
other genetic parameters, has become a major focus of biological marker research. Gliomas 
often possess decreased MGMT expression levels, which are thought to be primarily due to 
increased MGMT promoter methylation as previously mentioned. A correlation between 
MGMT promoter methylation and response of malignant gliomas to alkylating 
chemotherapy has been observed (Riemenschneider et al., 2010). MGMT hypermethylation 
has been identified in 11% of grade II astrocytoma, 27% of oligoastrocytoma, and 62% of 
oligodendroglioma cases (Bourne & Schiff, 2010). In addition, DNA hypermethylation was 
found in 36% of primary GBM and 75% of secondary GBM cases (Gladson et al., 2010). The 
heretofore reported frequencies of MGMT promoter methylation vary widely. In the 
EORTC-NCIC cohort, 45% of assessable cases had MGMT promoter methylation. In a series 
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of 102 patients with various grades and gliomas subtypes, Jha and colleagues found the 
presence of MGMT promoter methylation in 67.6% cases (79% in Grade II gliomas, 71% in 
Grade III gliomas, and 57% in GBM), suggesting an inverse relationship between 
methylation status and tumor grade (Jha et al., 2010). Purely oligodendroglial tumors 
showed the highest percentage of cases with MGMT promoter methylation (84%), compared 
with 63.5% in astrocytic tumors. The methylation status of MGMT promoter was not shown 
to be significantly associated with 1p/19q loss of heterozygosity, nor was there significant 
association of promoter methylation with EGFR amplification or TP53 mutation. 
 
 
Table 1. Common Alterations in Malignant Gliomas and their Putative Biomarker Status 
In the landmark EORTC/NCIC study by Stupp and colleagues, 573 patients with newly-
diagnosed GBM, 84% of which were surgically debulked, were randomized to receive RT 
alone (60 Gy in 30 fractions) or RT plus continuous daily TMZ (75 mg/m2 BSA from the first 
to the last day of RT), followed by six cycles of adjuvant TMZ (150-200 mg/m2 BSA for 5 
days during each 28-day cycle). At a median follow-up of 28 months, the median survival 
was 14.6 months with RT plus TMZ versus 12.1 months with RT alone, rendering the hazard  
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Table 1. Recent clinical trials with targeted therapy. OS - overall survivial. PFS - progression 
free survival. MTD - maximum tolerated dose. SD - stable disease. PR - partial response. CR 
- complete response. GBM - glioblastoma. AA - anaplastic astrocytoma. RT - radiation 
therapy. TMZ - temozolomide. BEV – bevacizumab. (Bogdahn, 2009; Chang, 2009; Soffietti, 2009; 
Batchelor et al., 2010; Brandes et al., 2010; Drappatz et al., 2010; Hainsworth et al., 2010; Hasselbalch et 
al., 2010; Reardon et al., 2010; Sarkaria et al., 2010; Sathornsumetee et al., 2010; Stupp et al., 2010; Wick et 
al., 2010; Lai et al., 2011; Altaha, June 2010; Benouaich-Amiel, June 2010; Blakeley, June 2010; 
Chinnaiyan, June 2010; Drappatz, June 2010; Fink, June 2010; Mcnicol, June 2010; Schiff, June 2010; Wen, 
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June 2010; Butowski, May 2009; Chi, May 2009; De Groot, May 2009; Desjardins, May 2009; Fiveash, 
May 2009; Frentzas, May 2009; Friedman, May 2009; Gilbert, May 2009; Gruber, May 2009; Herndon, 
May 2009; Kirkpatrick, May 2009; Lamar, May 2009; Mason, May 2009; Neyns, May 2009; Prados, May 
2009; Raizer, May 2009; Supko, May 2009; Wen, May 2009) 
ratio (HR) for death 0.63 in the combined modality group. Moreover, the two-year overall 
survival (OS-2) was 26.5% with RT+TMZ and 10.4% with RT alone (Stupp et al., 2005). The 
5-year analysis showed that OS-5 was 9.8% with RT and TMZ, versus 1.9% with RT alone 
(Stupp et al., 2009). In this trial, patients whose tumor had a methylated MGMT gene 
promoter had improved survival (median 21.7 versus 12.7 months, OS-2 46% versus 13.8%) 
relative to those with an unmethylated MGMT promoter, and the methylation status was 
the strongest predictor for outcome and benefit from TMZ chemotherapy (Hegi et al., 2005). 
Another study analyzing 125 patients with GBM showed that MGMT promoter methylation 
was associated with improved median overall survival (61 weeks vs. 42 weeks) (Ang et al., 
2010). These studies suggest that MGMT promoter methylation status could possibly be 
used as a strong predictive marker of response to chemotherapeutic alkylating agents. 
Furthermore, it is thought that the benefit of MGMT promoter hypermethylation only 
applies to chemotherapy. However, one study suggested that decreased MGMT confers 
sensitivity to radiation alone, as well (Rivera et al., 2010). However, this remains 
controversial as it is thought that this observation is due to the overall prognostic value of 
MGMT and is independent of the treatment type (Riemenschneider et al., 2010). 
Given the increased prevalence of MGMT promoter methylation in lower grade tumors, the 
effectiveness of adjuvant monotherapy with TMZ has been tested in a trial setting, with 
reported response rates of up to 52%. Kesari and colleagues conducted a phase II study of 
protracted daily TMZ (75 mg/m2/d for 49 consecutive days of each cycle, followed by 28 
days off between cycles, until evidence of progression or unacceptable toxicity for a 
maximum of six cycles) in 44 patients with newly diagnosed low-grade glioma. After a 
median follow-up of 39.4 months, 21 patients progressed with an overall median 
progression-free survival of 38 months (Kesari et al., 2009). Patients with methylated MGMT 
promoter had a significantly longer overall survival (100% alive at analysis, versus 29 
months with unmethylated promoter), as did patients with single or co-deleted 1p or 19q. 
The efficacy of protracted TMZ for the treatment of low grade gliomas was also shown in 
another series with 25 patients, with a response rate of 52%, and a relatively well-tolerated 
toxicity profile (Pouratian et al., 2007).  
An even more pressing clinical challenge is improving the chemotherapy response in GBM 
patients without the MGMT promoter methylation. Optimizing the adjuvant chemotherapy 
regimen is one potential strategy to improve patient outcomes, given the inverse 
relationship between the level of tumoral MGMT and chemosensitivity. A randomized 
Phase II trial of adjuvant dose-dense (150 mg/m2 days 1 to 7 and 15 to 21) or metronomic (50 
mg/m2 continuous daily) TMZ showed that the former approach conferred a 1 year survival 
of 80%, median survival 17.1 months and PFS-6 months of 56% (Clarke et al., 2009). 
Specifically, in the unmethylated MGMT subset, the median survival was 15.4 months, 
which was superior to the 12.7 months reported for the patients with unmethylated MGMT 
in the EORTC/NCIC trial. The dose-dense TMZ schedule suggests that the more effective 
inhibition of MGMT may be most beneficial to GBM patients with unmethylated MGMT 
promoter. 
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In patients that do not have suppressed levels of MGMT, O6-benzylguanine can be used as a 
MGMT-inactivating agent. This treatment has shown synergistic effects in combination with 
TMZ and RT in several pre-clinical models (Wedge et al., 1997; Noda et al., 2009). However, 
GBMs often have decreased concentrations of MGMT, which could make these tumors more 
susceptible to TMZ (Jansen et al., 2010). Decreased MGMT appears to serve a prognostic role 
in GBM, as a recent study showed that 46% of patients with MGMT-methylated tumors 
were alive at 2 years versus 23% of unmethylated patients when treated with RT plus TMZ 
(Jansen et al., 2010). MGMT promoter methylation as a biomarker in grade II gliomas 
remains controversial. However, for grade III gliomas MGMT promoter hypermethylation 
appears to be a positive prognostic marker and for grade IV it is believed to be a prognostic 
as well as a predictive marker for alkylating agent chemotherapy (Riemenschneider et al., 
2010; Tabatabai et al., 2010). Furthermore, it is believed that the predictive power of MGMT 
is only for chemotherapy, although this remains a controversial topic as discussed before 
(Riemenschneider et al., 2010). Moreover, MGMT promoter methylation has been shown to 
be closely linked to pseudoprogression (Nutt, 2005; Riemenschneider et al., 2010). Although 
MGMT can be useful as a marker of survival, the current standard of care for GBM does not 
require knowing MGMT status; however, it may help distinguish between 
pseudoprogression and true progression (Nutt, 2005; Riemenschneider et al., 2010) as well 
as possibly determining if a MGMT-specific inhibitor should be combined with the current 
standard treatment modality.  
2.6 Other pathways 
2.6.1 Glutamatergic system 
The glutamatergic system has been found to play a key role in the proliferation, survival 
and migration of gliomas (Ishiuchi et al., 2007; De Groot et al., 2008). Glioma cells release 
glutamate in concentrations that are toxic to surrounding neurons and glia (Takano et al., 
2001). However, the glutamate reuptake is reduced due to downregulation of glutamate 
transporters (EAAT2/GLT-1) (Ye et al., 1999). In a phase II trial with talampanel, an oral 
noncompetitive antagonist of ┙-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
(AMPA) glutamate receptor and standard RT + TMZ in patients with newly diagnosed 
glioblastoma, a median survival of 18.3 months was reached in all patients. In patients 70 
years or younger, the median survival was 20.3 months. The two year survival was also 
superior compared with EORTC RT + TMZ data (41.7% vs 26.5%, respectively) (Grossman 
et al., 2009). 
2.6.2 Epigenetic regulation 
Histone deacetylases (HDAC) are enzymes that affect acetylation status of histones, as well 
as that of cell cycle regulatory proteins (Arts et al., 2003). Histone deacetylation leads to tight 
coiling of chromatin and silencing of expression of various genes, including those 
implicated in the regulation of cell survival, tumor cell differentiation, cell cycle arrest and 
apoptosis (Jones & Baylin, 2002). North Central Cancer Treatment Group (NCCTG) 
conducted a Phase II trial of vorinostat, a small-molecule inhibitor of human HDAC1, 2, 3, 6 
and 8 that crosses the blood-brain barrier, in 66 patients with recurrent glioblastoma 
(Galanis et al., 2009). The agent was administered at a dose of 200 mg twice a day for 14 
days every 3 weeks, and was well tolerated. The 6-month PFS was 15.2%, with median time 
to progression of 1.9 months and median survival of 5.7 months. However, in patients who 
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were progression-free at 6 months, the duration of disease stability ranged from 6.8 to 28+ 
months, suggesting that there is a patient sub-population that can derive definite clinical 
benefit from this therapy. Incorporation of vorinostat in the current standard of care with RT 
+ TMZ will be tested by the NCCTG/North American Brain Tumor Coalition in a phase I/II 
trial. 
3. Conclusion 
As we learn more about cellular pathways and effectors involved in gliomagenesis, there 
will likely be a paradigm shift from the uniform standard-of-care treatment for all patients 
to a more individualized treatment based on molecular biomarkers. The aforementioned 
novel targeting therapies add to our armamentarium both as single agents and in 
combination with radiation, chemotherapy, and other targeted molecular agents. 
Ultimately, this will enable us to devise a more effective treatment strategy by tackling the 
underpinnings of resistance of malignant gliomas. As our knowledge increases, the 
challenge before the scientific and clinical community will be to identify the key targets and 
formulate therapy accordingly. Foregoing the "kitchen sink" approach will lessen the harm 
done to patients, as the aforementioned clinical trials show that targeted therapies may 
cause serious toxicities.  
Although most studies mentioned are phase I or II, with a relatively short follow-up time, 
several of these agents warrant testing in a larger and randomized setting to truly discern 
their efficacy and safety, with the overarching hope of improving our patients’ prognosis. 
The most recent update from Stupp and colleagues regarding integrin inhibition with 
addition of cilengitide to standard chemoradiotherapy shows promise to potentially become 
the new standard-of-care for patients with GBM, suggesting that the most effective strategy 
is to target both the extracellular (e.g., integrin) and intracellular effectors. Moreover, just as 
the methylation status of the MGMT promoter did, greater characterization of gene 
expression by epigenetic regulation may help us elucidate additional mechanisms of 
resistance or sensitivity to therapy.  
In summary, gaining a better understanding of the molecular brain tumor population(s) that 
benefit from each targeted therapy will lead to more effective personalized therapy. It is 
hoped that a more targeted therapeutic approach will overcome the current limitations in 
the treatment of patients with malignant gliomas and result in a better prognosis for patients 
with brain tumors.  
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